Strong evidence show that TGF-b reduces the surface expression of crucial activating receptors (NKp30 and NKG2D) on NK cells and elevated levels of this cytokine is associated with impaired activity of NK cells in cancer patients [112–115]. Here, KLRK1 is linked to cancer.